(Pembrolizumab + vibostolimab) is under clinical development by Merck and currently in Phase II for Metastatic Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Metastatic Renal Cell Carcinoma have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Pembrolizumab + vibostolimab)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Pembrolizumab + vibostolimab) overview

A fixed dose combination of pembrolizumab and vibostolimab (MK-7684A) is under development for the treatment of solid tumor including cervical cancer, hepatocellular carcinoma, endometrial cancer, biliary cancer, cholangiocarcinoma, adenocarcinoma of the gastroesophageal junction, non-small cell lung cancer, squamous non-small cell lung cancer, gallbladder cancer, esophageal cancer, head and neck cancer squamous cell carcinoma, esophageal squamous cell carcinoma, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, triple-negative breast cancer (TNBC), small cell lung carcinoma, transitional cell carcinoma (urothelial cell carcinoma), urothelial carcinoma of renal pelvis, ureter cancer, bladder cancer, urethral cancer, ovarian cancer, gastric cancer and hematological tumors including relapsed/refractory classic Hodgkins Lyphoma (cHL), Primary mediastinal B-cell lymphoma (PMBCL), Follicular Lymphoma (FL), Diffuse large B-cell lymphoma (DLBCL) or Non-Hodgkins Lymphoma (NHL), or multiple myeloma (MM), Mantle Cell Lymphoma, non muscle invasive bladder cancer, metastatic clear cell renal cell carcinoma (ccRCC). It is a fixed dose formulation of pembrolizumab and vibostolimab and is administered through intravenous route. Pembrolizumab acts by targeting programmed cell death protein 1 (PD1) and vibostolimab by TIGIT protein.

It was under development for the treatment of melanoma.

Merck overview

Merck is a biopharmaceutical company with focus on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. It offers prescription products for the treatment of cardiovascular conditions, cancer, immune disorders, infectious and respiratory diseases, and diabetes, among others. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors, and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is headquartered in Rahway, New Jersey, the US.

For a complete picture of (Pembrolizumab + vibostolimab)’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.